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Abstract: Malaria is an infectious disease causing at least 1 million deaths per year, and, 
unfortunately, the chemical entities available to treat malaria are still too limited. In this 
review we highlight the contribution of marine chemistry in the field of antimalarial 
research by reporting the most important results obtained until the beginning of 2009, with 
particular emphasis on recent discoveries. About 60 secondary metabolites produced by 
marine organisms have been grouped into three structural types and discussed in terms of 
their reported antimalarial activities. The major groups of metabolites include isonitrile 
derivatives, alkaloids and endoperoxide derivatives. The following discussion evidences 
that antimalarial marine molecules can efficiently integrate the panel of lead compounds 
isolated from terrestrial sources with new chemical backbones and, sometimes, with 
unique functional groups. 
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1.  Introduction  
 
Malaria is an infectious disease caused by several protozoans belonging to the genus Plasmodium 
(P. falciparum, P. ovale, P. vivax, P. malariae), with P. falciparum (Pf) being the parasite responsible 
for most severe diseases and most fatal cases. The protozoan comes in contact with humans through 
the vector contribution of female mosquitoes of the genus Anopheles, then it invades red blood cells 
causing anaemia; the ensuing rupture of infected erythrocytes is associated with the release into the 
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blood stream of cell debris responsible for the characteristic fever spike patterns. In lethal cases, a 
specific protein produced by the protozoan is embedded into the cell membrane of the infected 
erythrocyte and, as a consequence of this modification, the erythrocyte sticks to the walls of capillaries 
causing obstruction of vessels. When this mechanism operates at the level of brain vessels, the loss of 
consciousness is the first symptom, but, if this form of cerebral malaria is not treated immediately, it is 
soon followed by death. 
The improvement of hygienic conditions, the massive use of insecticides, and the discovery of 
different drugs played a great role in the nearly complete extinction of infections registered in 
developed countries. Unfortunately, in the tropical countries of Africa, Asia and America, malaria is 
still a common cause of death (each year, 300-500 million people become ill with malaria and 1-3 
million die) and tragically most of the victims are children under the age of five: every 30 seconds a 
child dies of malaria [1]. A troublesome increase in the number of fatal cases has been registered in 
recent years and this is principally due to the spread of multi-drug resistant strains of Plasmodium, that 
make ineffective the limited armamentarium of drugs now available. Since malaria is a disease of 
worldwide implications and almost half of the world’s population is currently at risk for malaria 
infection, combating malaria is one of the highest priority programs of WHO [2]. 
  
Unfortunately, in spite of several years of efforts and a number of announcements, a vaccine against 
malaria has not yet been found and the number of different strains causing the pathology and their 
tendency to genetic mutations promise to create difficulties to this strategy also in the future. Moderate 
optimism has recently been arisen by RTS,S vaccine, heading phase III trials in 2009, but its potential 
protective efficacy has been estimated not higher than 30%-40% and only when the vaccine is used in 
combination with an effective adjuvant therapy [3].   
On the other hand, the impressive progresses in the field of genetic research have allowed the 
sequencing of the entire genome of both the malarial parasite and its insect vector; this important result 
disclosed a host of pharmaceutical targets to prevent and/or treat the disease [4]. Therefore, the 
pharmacological therapy has been in the past and currently remains the best answer that researchers 
have proposed against malaria. Unfortunately, the number of drugs active against malaria continues to 
be very small and the selection of resistant strains is further narrowing the number of effective 
molecules. In the last 30 years about 1,700 new drugs have been registered and, among them, only 15 
were destined to tropical diseases and only 4-5 against malaria. This picture dramatically illustrates the 
unquestionable evidence that efforts of pharmaceutical companies are obviously not proportional to 
the number of deaths for a certain pathology but mostly to the potential market of the developed drugs.  
 
Figure 1. Chloroquine (1) and mefloquine (2) 
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The available chemical entities to treat malaria cases are sadly based on very old molecules, like the 
chloroquine analogues (Figure 1). Although the combination of these molecules with artemisinin and 
other endoperoxide analogues is giving some good results, the therapeutic choices are still too limited. 
There is therefore an urgent need for new and innovative drugs. According to Jefford, a drug directed 
against plasmodium should be active orally for 1-3 days, should give a fast eradication of parasite and 
disappearance of symptoms, should be safe for children and pregnant women, and, more importantly, 
should be as cheap as aspirin (<1€ per treatment) [5].  
To reach this challenging aim, the identification and selection of new lead compounds constitutes a 
crucial point. In this regard, living organisms are a recognized source of potentially bioactive 
molecules which are, commonly, more effective than those obtained through combinatorial synthetic 
chemistry. Indeed, synthetic libraries are straightforward to assemble, this representing an advantage 
but also a drawback: the use of a relatively limited number of synthetic reactions as well as of 
structurally diverse building blocks to library construction implies that combinatorial libraries often 
lack the structural diversity required for fully exploring the biological space. On the other hand, having 
been enzymatically engineered and biologically validated, the “quality” of both terrestrial and marine 
natural products is higher and they represent the ideal tool to harvest the fruits encrypted in a genomic 
text.  
Thus, not surprisingly, the most significant advancements in malaria therapy have been made with 
the introduction of natural leads. The treatment of malaria infections holds a venerable place both in 
the history of medicinal chemistry and of natural product chemistry. Indeed, malaria was the first 
disease to be treated with an active principle isolated from a natural source, quinine, isolated from the 
Cinchona bark in 1820, and until the 20
th century many of the active medicines were developed based 
on the structure of quinine. A more recent breakthrough in the fight against malaria came with the 
discovery of artemisinin, an endoperoxide sesquiterpene from Artemisia annua [6], an herbal remedy 
used in Chinese folk medicine. It is now expected that the next significant advancement in the field of 
antimalarial drugs will not be reached through the discovery of a single potent compound, but through 
the introduction of an innovative drug to be used in a combined therapy, preferably composed by 
molecules acting at different stages of the malaria parasite life cycle.  
Hopefully, the new breakthrough in the malaria treatment will come with the development of a 
marine lead compound. The incredible potential of even a single marine organism (mostly 
invertebrates, as sponges, tunicates, soft corals) to produce a large array of secondary metabolites can 
be interpreted by considering the common features of the secondary metabolism in all the living 
organisms as well as some peculiar features of the marine environment. In addition, the contribution of 
the symbiotic population to the metabolic work of a marine invertebrate is an important point to be 
taken into account. Indeed, marine invertebrates harbor in their tissues a series of microorganisms such 
as bacteria, cyanobacteria and fungi and, in some cases, associated micro-organisms may constitute up 
to 40% of the biomass [7,8], this bacterial concentration exceeding that of the surrounding sea water 
by two or three orders of magnitude. Although the real contribution of the microorganisms to the 
secondary metabolism of marine invertebrates has not yet been fully evaluated, essentially because of 
the difficulties encountered in culturing sponge-associated bacteria, it is generally accepted that these 
harbored microorganisms play a significant role in the biosynthesis of the natural products isolated 
from the invertebrate. Furthermore, the recent impressive advances in molecular genetics, currently Mar. Drugs 2009, 7                                                  
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allowing the identification of biosynthetic genes in the producing organisms and their cloning in 
bacteria suitable for large-scale fermentation [9] could represent a solution for the problem of 
compound supply. If these techniques will be fully developed and utilized, the last obstacle to consider 
marine organisms as a potentially sustainable drug source would be overcome. 
This review aims at highlighting the contribution of marine chemistry in the field of antimalarial 
research, by reporting the most important results obtained until the beginning of 2009, with particular 
emphasis on recent discoveries. We have decided to include in this review all those compounds 
possessing a moderate to high antimalarial activity, thus excluding very weak antimalarials or 
molecules for which the toxicity toward Plasmodium strains is not specific and/or is clearly due to a 
general cytotoxicity. An interesting review has been recently published focusing on the synthesis of 
marine natural products with antimalarial activity [10]; consequently, we will not discuss in detail 
synthetic efforts aimed at preparing marine antimalarial leads.  
Following a scheme that we have introduced in a recent book chapter [11], marine antimalarials 
have been divided throughout this review, according to their chemical structures, into three different 
classes: i) isonitrile-containing derivatives; ii) alkaloids; iii) endoperoxides. A paragraph including 
miscellaneous compounds not belonging to the above classes is presented at the end of the review.  
 
2.  Isonitrile-containing derivatives and their analogues 
 
The parent compound of the small class of isonitrile-containing marine secondary metabolites is 
axisonitrile-1 (3, Figure 2), isolated in 1973 from the marine sponge Axinella cannabina, where it co-
occurred with the strictly related axisothiocyanate-1 (4) [12]. Axisonitrile-1 was soon followed by 
other isonitrile-, isothiocyanate-, and formamide-containing sesquiterpenoids from the same source, 
namely axamide-1 (5), axisonitrile-2, (6) [13], axisothiocyanate-2 (7), axamide-2 (8) [14], axisonitrile-
3 (9), axisothiocyanate-3 (10), and axamide-3 (11) [15] (Figure 2). 
 
Figure 2. Isonitrile-, isothiocyanate- and formamide-containing sesquiterpenoids from the 
sponge Axinella cannabina. 
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The chemical structure of these derivatives has been confirmed by elegant syntheses, including the 
very recent total synthesis of axamide-1 and axisonitrile-1 via 6-exo-dig radical cyclization [16]. In 
1992, axisonitrile-3 (9) was re-isolated from the sponge Acanthella klethra Pulitzer-Finali and found to 
possess a potent antimalarial activity both on chloroquine-sensitive (D6, 142 ng/mL) and chloroquine-Mar. Drugs 2009, 7                                                  
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resistant (W2, 17 ng/mL) P. falciparum strains [17], and to be practically devoid of cytotoxicity 
toward KB cells. The closely related axisothiocyanate-3 (10) was inactive, suggesting that the 
antiplasmodial activity should not (or, at least, not only) be ascribed to structural features of the carbon 
backbone but should be strictly dependent on the presence of the isonitrile functional group.  
These remarkable findings stimulated an in-depth research activity aimed at isolating and testing 
isonitrile secondary metabolites from different marine sources, with particular regards to marine 
sponges of the families Axinellidae and Halicondridae appearing to selectively elaborate these kinds of 
metabolites. The chemical analysis of the sponge Cymbastela hooperi (Axinellidae) afforded a series 
of diterpenes based on amphilectane, isocycloamphilectane, and neoamphilectane skeletons and 
bearing isonitrile, isothiocyanate, and the rare isocyanate functionalities (Figure 3) [18]. These 
molecules displayed a significant (low nM range) and selective (cytotoxicity in the μM range) in vitro 
antimalarial activity and the co-occurrence of several strictly related analogues suggested some 
structure-activity relationships.  
 
Figure 3. Representative isonitrile- and isothiocyanate-containing diterpenoids isolated 
from the marine sponge Cymbastela hooperi.  
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Comparison among the activities exhibited by the closely related isocycloamphilectanes 12 (IC50 ~ 
4 ng/mL), 13 (IC50 ~ 40 ng/mL), and 14 (IC50 ~ 60 ng/mL) illustrated the relative potency of isonitrile, 
isothiocyanate and isocyanate groups, supporting the previous observation that the bioactivity is 
particularly associated to the presence of the isonitrile group. However, the location of functional Mar. Drugs 2009, 7                                                  
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groups also plays a role, as suggested by the comparison between the activities of compounds 14 and 
15 (IC50 ~ 3 ng/mL), where the positions of isocyanate and isonitrile groups are interchanged. 
The importance of the isonitrile group is highlighted by the relatively low activity of the 
amphilectane isothiocyanate 18 (IC50 ~ 800 ng/mL), and by the similarly low activity of amphilectane 
formamides, very recently isolated from the same source [19]. On the other hand, the activity of the 
neoamphilectane derivative 19 (IC50 = D6, 90 ng/mL; W2, 30 ng/mL) is considerably higher than that 
of compound 16, indicating that the carbon skeleton can modulate the antiplasmodial activity of 
isonitrile derivatives.  
Further isonitrile-containing antimalarial derivatives have been isolated from the Japanese sponge 
Acanthella  sp. (e.g. 20-21, Figure 4) [20]. These molecules belong to the class of the kalihinane 
diterpenoids, which comprises also antifungal, anthelmintic and antifouling compounds. Isonitrile 
kalihinanes showed a potent antiplasmodial activity in the very low nanogram range [e.g. kalihinol A 
(21) IC50 = 0.4 ng/mL]. A total synthesis of a kalihinol A analogue has been accomplished [21].  
 
Figure 4. Representative kalihinane diterpenoids isolated from the marine sponge Acanthella sp. 
 20
H
OH
NC
H
O
NC
 21
H
H
NC
H
HO
NC O
Cl
 
 
A hybrid modelling technique combining 3D-QSAR with quasi-atomistic receptor modelling 
methodologies has been used to generate a pharmacophore hypothesis for isonitrile derivatives 
consistent with the experimental bioactivities, indicating a likely mechanism of action for this class of 
marine antimalarials [22]. Active isonitriles were demonstrated to interact with free heme by forming a 
coordination complex with the iron center; the “pharmacophore” must possess an overall lipophilic 
rigid molecular core comprising at least a tricyclic framework carrying an isonitrile group and 
establishing further hydrophobic interactions above the ring plane. Interaction of marine isonitriles 
derivatives with heme could inhibit the transformation of heme into β-hematin and then hemozoin, a 
polymer produced by Plasmodium in order to neutralize the toxic (detergent-like) free heme produced 
in the food vacuole. In addition, isonitriles were shown to prevent both the peroxidative and 
glutathione-mediated destruction of heme under conditions that mimic the environment within the 
malaria parasite. Thus, isonitriles exert their antiplasmodial activity by preventing heme detoxification 
[22].  
 
3.  Alkaloids 
 
Manzamines are undoubtedly the most important and potent antimalarial alkaloids isolated from 
marine sources. They are very complex polycyclic (7-8 rings or more) alkaloids first reported by Higa 
and coworkers in 1986 from an Okinawan sponge belonging to the genus Haliclona [23,24]. These Mar. Drugs 2009, 7                                                  
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molecules are characterized by an intricate pentacyclic heterocyclic system attached to a β-carboline 
moiety. Since the first report of manzamine A (22, Figure 5), at least 60 additional manzamine-type 
alkaloids have been reported from taxonomically unrelated sponges belonging to different genera (e.g. 
Xestospongia,  Ircinia, and Amphimedon) and different orders. These findings strengthen the 
hypothesis that manzamines are not true sponge metabolites but, more likely, they have a symbiotic 
origin. Accordingly, microbial community analyses for one of the most common manzamine 
producing sponges resulted in the identification of Micronosphora  sp. as the bacteria producing 
manzamines [25]. A recent paper hypothesized a common biosynthetic route for cyclostellettamines, 
halicyclamines and manzamines, thus highlighting the existence of “nature diversity-oriented 
syntheses” [26]. 
 
Figure 5. Chemical structure of manzamine A (22) and manzamine F (23) 
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Fourteen years after its first isolation, Hamann et al. disclosed the antimalarial potential of 
manzamine A [27]. This molecule, and its 8-hydoxy derivative, were found to potently inhibit the 
growth of Plasmodium falciparum both in vitro (IC50 ~ 5.0 ng/mL) and in vivo (a parasitemia 
suppression of the same order of magnitude of that of artemisinin). Unfortunately, the therapeutic 
index of these molecules is somewhat narrow (gastrointestinal distress) and further studies are needed 
to improve this value.  
Interestingly, a closely related derivative of manzamine A, manzamine F (23, Figure 5), is 
completely devoid of activity (IC50 > 1,000 ng/mL), thus evidencing the key role of the eight 
membered ring, where the differences between the inactive manzamine F and the active manzamine A 
are confined. The reduction of the double bond and/or the insertion of a ketone group on the adjacent 
carbon is evidently deleterious for the antimalarial activity. Similarly, the attachment of the hydroxyl 
group at position 6, in place of position 8, has a deleterious impact on the antimalarial activity, as 
indicated by the lower potency of manzamine Y (6-hydroxy-manzamine A), exhibiting IC50 ~ 600 
ng/mL [28]. 
Additional information on structure-activity relationships came with the isolation of neo-
kauluamine (24, Figure 6) a very complex molecule constituted by two manzamine units dimerized 
through ether linkages between the eight-membered rings [29]. Although this molecule, like 
manzamine F (23), lacks the double bond in the eight-membered ring, it demonstrated the same Mar. Drugs 2009, 7                                                  
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antimalarial activity as manzamine A. The lack of antimalarial activity for 12,34-oxamanzamine A 
(25, Figure 6) (IC50 = 5 μg/mL) [30] indicates that the C-12 hydroxyl, the C-34 methine or the 
conformation of the eight-membered ring are of key importance for the antimalarial activity. The 
crucial role of the hydroxy group at position 12 has also been highlighted by a recent study reporting 
that acetylation at position 12 significantly reduced the antimalarial activity [31]. 
 
Figure 6. Chemical structures of neo-kauluamine (24) and 12,34-oxamanzamine A (25). 
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Manzamines have also been reported to be antiinflammatory, antifungal, antibacterial and 
antitubercolosis agents, and to exhibit activity against AIDS opportunistic pathogens (e.g. Toxoplasma 
gondii) [29, 32, 33]. More recently, inhibitory activity against glycogen synthase kinase-3 (GSK-3) has 
been discovered for manzamine A and derivatives [34]. The inhibited kinase is involved in 
pathological hyperphosphorylation of protein tau and, therefore, manzamine A constitutes a promising 
scaffold to design potential therapeutic agents for Alzheimer’s disease. The highly complex structure 
of manzamines have made them an attractive total synthesis target, and three different total syntheses 
have been published [35-37]. 
Figure 7. Chemical structure of homofascaplysin A (26)  
 
 
 
 
The β-carboline group is also present in the structure of homofascaplysin A (26, Figure 7), isolated 
from the sponge Hyrtios erecta [38]. This alkaloid showed activity against chloroquine-resistant P. 
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falciparum strains with an IC50 of about 20 ng/mL, but its toxicity toward rat skeletal muscle myoblast 
cells was estimated to be less than 1 μg/mL. 
Lepadins are decahydroquinoline derivatives bearing a linear eight-carbon chain obtained from two 
marine invertebrates of Australian origin, Clavelina lepadiformis [39] and Didemnum  sp. [40]. 
Lepadin E (29, Figure 8) exhibited a significant antimalarial activity (IC50 =  400 ng/mL) while its 
close analogues lepadin B (27) and D (28) (Figure 8) are almost completely inactive. This marked 
difference of activity highlights the importance of the 2E-octenoic acid ester functionality in place of 
the secondary alcohol. Authors have proposed that this conformationally mobile side-chain could serve 
to stabilize non-bonding interactions with heme, or with any other “receptor” molecule. On the other 
hand, lepadin B has been found to block neuronal nicotinic acetylcholine receptors [41]. A number of 
total syntheses of lepadins have been accomplished [42]. 
 
Figure 8. Chemical structures of lepadins B (27), D (28) and E (29). 
 
 
 
 
 
 
 
 
 
 
Phloeodictynes are a class of marine alkaloids whose chemical structure appears to be related to 
that of lepadins in having a bicyclic nitrogen-containing skeleton bearing a long alkyl chain. 
Phloeodictynes, isolated from sponges belonging to the genus Oceanapia [43, 44], are 1,2,3,4-tetra-
hydropyrrolo-[1,2-a]-pyrimidinium derivatives bearing at C-6, in addition to an OH group, a variable-
length alkyl chain and at N-1 a four/five methylene chain ending in a guanidine group.  
Phloeodictyn 5,7i (30, Figure 9) exhibited a good activity (IC50 = 300 ng/mL) against the 
chloroquine-resistant FGB1 strain of the malaria parasite Plasmodium falciparum, with a good 
therapeutic index [44]. Total synthesis for these molecules has been reported [45]. 
 
Figure 9. Chemical structure of the active compound phloeodictyn 5,7i (30). 
 30
N
N
OH
HN
NH
NH2
8
4
 
 27  28
N
H
H
H
O
OH
O
N
H
H
H
OH
OH
N
H
H
H
OH
 29Mar. Drugs 2009, 7                                                  
 
 
139
6-Bromoaplysinopsin (31, Figure 10) is a simple indole derivative first isolated in 1985 [46] and 
later re-obtained from the sponge Smenospongia aurea [47], active against the D6 clone of P. 
falciparum with IC50 = 340 ng/mL and a low selectivity index. Heptyl prodigiosin (32, Figure 10) is a 
pigment, purified from a culture of α-proteobacteria isolated from a marine tunicate, which showed an 
antimalarial activity similar to that of quinine against the chloroquine–sensitive strain P. falciparum 
3D7 with an in vitro activity that was about 20 times the in vitro cytotoxic activity against mouse 
lymphocytes. When this molecule was tested in vivo, a single administration of 5 mg/kg significantly 
extended the survival of P. berghei ANKA strain-infected mice but, unfortunately, the same dose 
caused sclerotic lesions at the site of injection [48].  
 
Figure 10. Chemical structures of 6-bromoaplysinopsin (31) and of heptylprodigiosin (32). 
 
 
 
 
 
 
 
All the above marine alkaloids are characterized by a relatively poor knowledge of the mechanism 
of their antimalarial action, which is quite important to develop more potent and/or structurally 
simplified analogues. On the other hand, a couple of recently published antimalarial marine alkaloids 
have been found in the frame of investigations addressed against specific parasite targets. 
Oroidin (33, Figure 11), the parent compound of a well-known class of marine alkaloids [49, 50], 
has been found to inhibit Plasmodium falciparum enoyl-ACP reductase (IC50 = 0.30 μg/mL), an 
enzyme involved in the parasite fatty acid biosynthesis [51]. Further studies on the numerous oroidin 
analogues could reveal the structural requirements to interact with this target.   
Salinosporamide A (34, Figure 11) is a γ-lactam alkaloid isolated from a marine bacterium of the 
new genus Salinispora [52]. This molecule has been found to be a potent parasite proteasome inhibitor 
and to possess a quite significant antimalarial activity in vitro (IC50 = 11.4 nM) [53]. Salinosporamide 
was determined to act in the erythrocytic stage and maintained its potent activity in a malaria mouse 
model with inhibition of the parasite growth in treated mice at extremely low doses (130 μg/kg).  
   
Figure 11. Chemical structures of oroidin (33) and salinosporamide A (34). 
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Although some total syntheses of salinosporamide have been reported [54, 55], as for manzamine 
A, the bacterial origin of salinosporamide should provide opportunities for a renewable supply of the 
compound without harvesting large quantities of marine invertebrates. Anyway, in this case, also the 
relatively simple chemical structure of salinosporamide A could play in favour of the further 
development of this molecule as antimalarial drug. 
 
4. Endoperoxides 
 
One of the more substantial breakthroughs in malaria chemotherapy has been the discovery and 
development of endoperoxide-containing drugs. Research in this field began with the discovery that 
artemisinin (35,  Figure 12), an endoperoxide cadinane sesquiterpene lactone possessing a 1,2,4-
trioxane moiety, isolated from Artemisia annua (Compositae) leaves, possessed nanomolar activity 
also against chloroquine-resistant strains of Plasmodium [6, 56]. With its unique juxtaposition of 
peracetal, acetal and lactone functionalities, artemisinin possesses structural features very appealing to 
organic chemists. Totally synthetic routes to artemisinin have been developed [57], but their 
complexity suggests that they will very unlikely supplant the natural extract as a drug supply. 
 
Figure 12. Chemical structure of artemisinin (35) and postulated mechanism of its action. 
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The endoperoxide linkage is an essential feature for antimalarial activity of artemisinin and of its 
derivatives (e.g. the oil-soluble artemether, the water-soluble artesunate). Indeed, according to the 
widely accepted mechanism of action, these molecule interact with the iron(II) center of the heme unit 
released during the digestion of hemoglobin. This yields to the cleavage of the peroxide bridge and to 
the consequent formation of oxygen-centered radicals which, after an intramolecular rearrangement, 
convert into free C-centered radicals. These should be toxic to the parasite through alkylation of 
“sensitive” macromolecular targets (Figure 12). A Ca
2+-dependent ATPase specific of P. falciparum 
(PfATP6) has been suggested as a potential target for these active species  [58]. 
Intense research activity is currently ongoing in many laboratories around the world in order to 
obtain from natural sources endoperoxide derivatives which could constitute a valuable alternative to 
artemisinin. In this context, the next two sections will provide a survey of the contribution in this field 
coming from marine chemists. For clarity, these molecules have been divided in two categories Mar. Drugs 2009, 7                                                  
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according to their postulated (and only in few cases unambiguously demonstrated) biogenetic origin: 
polyketides and terpenoids. 
 
4.1. Polyketides 
 
Marine sponges belonging to the family Plakinidae contain a series of simple endoperoxide 
derivatives that have been identified as polyketide metabolites possessing six- or five-membered 1,2-
dioxygenated rings (1,2-dioxane or 1,2-dioxolane, respectively). A further variation is represented, in 
some cases, by the presence of a 3-methoxy substitution, building a peroxyketal group.  
Plakortin (36, Figure 13) was isolated more than 25 years ago from Plakortis halichondroides [59] 
and recently re-isolated in remarkable amounts from the Caribbean sponge Plakortis simplex [60]. In 
the latter study the absolute configuration of the four stereogenic carbons of plakortin has been 
determined by means of chemical derivatization and reaction with chiral auxiliaries. The plakortin 
analogues, dihydroplakortin (37), 3-epiplakortin (38), plakortide Q (39) (Figure 13) have been 
obtained from the same sponge [60,61].  
 
Figure 13. Chemical structures of plakortin (36) dihydroplakortin (37), 3-
epiplakortin (38), and plakortide Q (39). 
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All these molecules exhibited a good antimalarial activity against D10, chloroquine-sensitive strain, 
and W2, chloroquine-resistant strain of P. falciparum, with a more potent activity on the W2 strain 
(IC50 ~ 180 ng/mL), devoid of cytotoxicity [62]. The chemical structure of these antimalarial leads is 
remarkably simple and they could constitute a good probe to investigate the mechanisms of action as 
well as structure-activity relationships. In this regard, a series of semisynthetic derivatives of plakortin 
(37) has been prepared [63] and their activity highlighted the crucial roles both of the “western” alkyl 
side chain and of the conformational behaviour of the dioxane ring in the light of the interaction with 
the heme planar target.  
Furthermore, strong evidence have been gathered about the plakortin production by a bacterial 
symbiot of the sponge Plakortis simplex [64]. Hopefully, an approach based on identification, cloning 
and expression of the gene cluster(s) for plakortin and related compounds from the metagenome of the 
sponge could allow the production of plakortin by easy and low-cost bacterial fermentation, thus 
fulfilling one of the essential requirements of next generation antimalarial drugs. 
Interestingly, plakortide L (40, Figure 14), isolated from a Jamaican sponge Plakortis sp. [65], 
plakortide O (41) and plakortide P (42), isolated from Plakortis halichondrioides [66], showed a very 
low  in vitro antimalarial activity (IC50 > 8 μg/mL), in spite of their similarity with the plakortin Mar. Drugs 2009, 7                                                  
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scaffold. The configurational changes around the dioxane ring and/or the differences in the alkyl side 
chains are evidently responsible for the marked decrease of activity. 
 
Figure 14. Chemical structures of plakortides L (40), O (41) and P (42). 
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A structurally related class of marine metabolites showing a good antimalarial activity is that of 3-
alkoxy-1,2-dioxane (peroxyketals) derivatives. In this class of molecules, the alkoxy substituent at 
position 3 could partly mimic the non-peroxidic oxygen atom of the 1,2,4-trioxane ring of artemisinin. 
The methyl esters of peroxyplakoric acids A3 (43, Figure 15) and B3 (44, Figure 15) isolated from 
Plakortis sp., showed IC50 = 50 ng/mL against P. falciparum with a good selective toxicity index 
(about 200) [67].  
 
Figure 15. Chemical structures of peroxyplakoric acids A3 (43) and B3 (44) methyl esters, 
of chondrillin (47) and of two synthetic analogues (45 and 46). 
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Through the syntheses of some analogues of these active compounds, some conclusions about the 
structural requirements within this class of antimalarials were drawn. For example, compound 45 
(Figure 15) proved to be almost completely inactive, whereas compound 46 (Figure 15) retained the in 
vitro activity of peroxyplakoric acid B3 methyl ester, indicating the importance of the side chain for the 
antimalarial activity [68]. Furthermore, it has been demonstrated that the in vivo antimalarial potency 
of these compounds is increased by transforming the ester group into an amide group [69].  
Finally, the low antimalarial activity observed for a marine endoperoxide strictly related to 
peroxyplakoric acid B3 methyl ester, namely chondrillin, (47,  Figure 15)  [70] indicates that the Mar. Drugs 2009, 7                                                  
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presence of a double bond within the 3-methoxy-1,2-dioxane skeleton is detrimental for the activity, 
although the role of the long saturated alkyl chain should also be taken into account. 
 
4.2. Terpenoids 
 
Unfortunately, very few endoperoxide-containing terpenoids isolated from marine sources have 
been tested for their antimalarial activity. Sigmosceptrellin A, (48, Figure 16), is a norsesterterpene 
derivative active against P. falciparum (IC50 ~ 450 ng/mL) [71]. Interestingly, the C-3 epimer of 48, 
named sigmosceptrellin B, (49) proved to possess an activity about four times lower in the same test 
[72]. This is a good demonstration of the importance of stereochemistry to determine the antimalarial 
activity in the series of 1,2-dioxane derivatives. 
 
Figure 16. Chemical structures of sigmosceptrellin A (48) and of its C-3 epimer 
sigmosceptrellin B (49). 
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Methyl-3-epinuapapuanoate, (50,  Figure 17), a norditerpene derivative isolated from the New 
Caledonian sponge Diacarnus levii [73], showed a moderate in vitro activity against chloroquine-
resistant strains of P. falciparum (IC50 = 1.2 μg/mL) [74]. When the molecule was tested against P. 
berghei in vivo, at the concentration of 25 mg/kg, a 56% growth inhibition was observed. 
 
Figure 17. Chemical structure of methyl-3-epinuapapuanoate (50). 
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5. Miscellaneous Compounds 
 
In this section we have grouped all the marine secondary metabolites endowed with antimalarial 
activity and not falling in one of the preceding groups, namely they do not contain an isonitrile or an 
endoperoxide group and they are not alkaloids. These molecules can be further divided into two 
structural categories, namely quinones and phenols, and peptides.  Mar. Drugs 2009, 7                                                  
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5.1. Quinones and Phenols 
 
In the frame of a search for Plasmodium  protein kinase inhibitors, the previously known 
xestoquinone (51, Figure 18) [75] proved to be a selective active inhibitor of Pfnek-1, a never-in-
mitosis/Aspergillus (NIMA)-related protein kinase of P. falciparum [76]. However, the in vitro 
antiplasmodial activity of xestoquinone was moderate (IC50 ~ 3 μM). A similar activity was exhibited 
by another marine quinone, ilimaquinone (52), isolated from the Australian marine sponge 
Dactylospongia elegans [77].  
 
Figure 18. Chemical structures of xestoquinone (51) and ilimaquinone (52). 
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A series of quinone derivatives, named alisiaquinones (e.g. alisiaquinone A, 53, Figure 19) 
structurally related to xestoquinone, have been isolated from an unidentified New Caledonian sponge 
[78]. Not surprisingly they showed an activity against Pfnek-1 and a micromolar antiplasmodial 
activity similar to those exhibited by xestoquinone. However, quite interestingly, alisiaquinone C (54), 
bearing an additional heterocycle formed by a taurine substituent, exhibited a submicromolar activity 
(IC50 ~ 0.1 μM) on P. falciparum and a competitive selectivity index on the different plasmodial 
strains. This higher activity of alisiaquinone C (54) resulted to be not related to a more potent 
inhibition of Pfnek-1 but to a significant inhibition of the plasmodial enzyme farnesyl transferase. 
 
Figure 19. Chemical structure of alisiaquinones A (53) and C (54). 
 
 
 
 
 
 
(S)-Curcuphenol (55, Figure 20) is a sesquiterpene phenol isolated from different marine sponges 
belonging to the genus Didiscus [79]. This molecule exhibited in vitro antimalarial activity with MIC 
of 3.6 μg/mL against the D6 clone of P. falciparum and of 1.8 μg/mL against the W2 clone. Another 
phenol-containing antimalarial marine metabolite is 15-oxopuupehenol (56), isolated from sponges of 
the genus Hyrtios, and representative of a distinctive family of sponge metabolites comprising also the 
quinol-quinone pair of avarol and avarone. Compound 56 exhibited in vitro activity against P. 
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falciparum with MIC of 2.0 μg/mL against the D6 clone of P. falciparum and of 1.3 μg/mL against the 
W2 clone [80]. 
 
Figure 20. Chemical structures of cucurphenol (55) and 15-oxopuupehenol (56). 
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5.2. Peptides 
 
Two modified cyclic hexapeptides, venturamides (e.g. venturamide A, 57, Figure 21), isolated from 
the marine cyanobacterium Oscillatoria  sp., exhibited a moderate activity against Plasmodium 
falciparum (IC50 ~ 6-7 μM) [81], with a good selectivity.  
A similar antimalarial profile was also exhibited by dragomabin (58, Figure 21), a linear alkynoic 
lipopeptide isolated from a Panamanian strain of the marine cyanobacterium Lyngbya majuscula [82]. 
Interestingly, the related non-aromatic dragonamide B (59, Figure 21), isolated from the same source, 
was completely devoid of activity. 
A further cyanobacterial peptide derivative, named gallinamide A (60, Figure 21) has been isolated 
from Schizothrix species. This highly functionalized peptide, containing the very unusual 4-(S)-amino-
2-(E)-pentenoic acid subunit and an N,N-dimethyl isoleucine terminus, exhibited a moderate in vitro 
antimalarial activity (IC50 = 8.4 μM) [83]. 
 
Figure 21. Chemical structures of venturamide A (57), dragomabin (58), dragonamide B 
(59), and gallinamide A (60).  
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Finally, a secondary metabolite belonging to a completely different class, a polyether (61, Figure 
22) obtained from the marine Streptomyces sp. H668, exhibited a significant in vitro antimalarial 
activity (IC50 ~ 150 ng/mL), with a good selectivity [84]. Some examples of non-marine antimalarial 
polyether compounds are also present in the literature [85]. These compounds are believed to act as 
ionophores, and, due to their lipophilic character they are particularly able to interact with the 
protozoan- infected cell membrane. 
 
Figure 22. Chemical structure of the polyether 61. 
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6. Conclusions 
 
Data reported in the preceding paragraphs clearly demonstrate that the marine environment contains 
a number of compounds that could serve as lead structures for the development of new classes of 
antimalarial drugs. The antimalarial marine molecules can efficiently integrate the panel of lead 
compounds isolated from terrestrial sources (as in the case of endoperoxide derivatives) with new 
chemical backbones and, sometimes, with unique functional groups (as in the case of isonitrile 
derivatives). Of course, the drug potential of the about 60 molecules reported in this review is not the 
same, being related to the potency, to the selectivity, to the toxicity, and to the availability of the 
compounds. Among them, some isonitrile containing diterpenes, manzamines, salinosporamide, and 
some polyketide endoperoxides could be indicated as the most promising candidates to future 
developments. In this regard, the possibility of producing these molecules through bacterial 
fermentation combined with genetic engineering is a key issue to increase the chances of their full 
pharmacological evaluation and their possible introduction in therapy.  
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